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XDiscussion
Dr Michael J. Weyant (Aurora, Colo). Dr Biscotti, I enjoyed
reading the article that you sent me well in advance. You and
your coauthors are to be congratulated for exploring these novel
ways of supporting our patients through lung transplants, because
we all know the incidence of needing to support these patients will
probably go up as we continue to do lung transplants.
You suggest from your study that ECMO may be a more bene-
ficial method of supporting these patients through lung transplant,
and you suggest the reasons for that are your decreased blood
transfusions, the circuit being simpler, and the mechanical injury
of the blood cells being less.
I have a few questions, but I thought this study overall was quite
novel, and I plan to adopt some of these practices in my own work
with lung transplants. The first is that in looking at the patients who
had ECMO support in the operating room, were there any conver-
sions from ECMO to standard CPB? If there were, what were the
reasons for that?
Dr Biscotti. There were several instances in which we had to
convert to CPB, and thesewere mostly because of difficulty in con-
trolling bleeding where we needed cardiotomy suction. We didn’t
want to use several rounds of the cell saver, which tends to deplete
factors and can create its own set of problems. We generally
convert to CPB from ECMO when we encounter extensive
bleeding.
Dr Weyant. It’s not ‘‘several,’’ it’s a small number, which I
actually don’t think you emphasized enough, because the vast ma-
jority of patients who went to the operating room didn’t have their
strategy changed. And so to a critic of the use of ECMO, for
example, for this purpose, that would be your defense. And I think
when you submit the final article, maybe emphasizing that will be
more important.
And the other thing is that about a third of the patients in the
ECMO group you are talking about have what you describe as cen-
tral ECMO cannulation. Now, we all know what central cannula-
tion might be, but can you elaborate more on the actual
cannulation strategy for central ECMO versus peripheral
ECMO? I’m assuming the difference is most likely the placement
of the arterial cannula, but how do you decide where to put it?
Dr Biscotti. We don’t typically do it in the same way as the
CPB. We often use a femoral venous drainage cannula and then
insert an aortic cannula for central support, which can be done
through either a clamshell or thoracotomy, which are our preferred
surgical approaches to the chest. This is because if the patient has a
good intrinsic cardiac output but poor lung function, the carotid
and coronary circulation will have inadequate oxygenated blood
because retrograde venoarterial ECMO does not provide good up-
per body perfusion. In those cases that where we have to convert
from our typical groin arterial cannulation to our central aortic
cannulation, we can maintain the same peripheral drainage. If
we have any doubts or notice a severe and persistent drop in
PaO2 from the right radial artery, we will use or convert to a central
ECMO cannulation strategy.The Journal of Thoracic and CarDrWeyant. For my final question, you mentioned your antico-
agulation strategy for both your standard CPB and ECMO. For
those who are going to institute ECMO more as a way of support-
ing their patients, you seem to run it a little looser, without moni-
toring of activated clotting time and so on. What would you
suggest for programs that would initiate more ECMO support
versus CPB support and the use of activated clotting times and
more firm monitoring of the anticoagulation process?
I thought your talk was great and really enjoyed reading your
article.
Dr Biscotti. Thank you; I appreciate that. Our intraoperative
anticoagulation approach was greatly influenced by our experi-
ence with our intensive care unit–managed ECMO patients. We
did manage them with activated clotting time during the infancy
of the ECMO program; however, after demonstrating that there
really was no difference in system failure or cannula issues
such as clotting, whether the activated clotting time was measured
or we just followed partial thromboplastin times every 6, 12, or 24
hours, we then transitioned to not using activated clotting times,
and that is our current intraoperative protocol. Our perfusionists
will check an activated clotting time after the initial heparin bolus
to confirm that it has increased from baseline, but that is the last
clinical use of activated clotting time during the operation. Also,
because the ECMO technology, specifically biocompatibility, has
improved so much in the last 5 to 10 years, I think that low anti-
coagulation levels are probably reasonable for a 3- to 6-hour
ECMO run.
DrDaniel L.Miller (Marietta, Ga). I had done lung transplants
for 20 years and stopped December 31st when I went to my new
position, and I can’t believe I am asking a lung transplant question.
But my question is, I saw about a third of your circulatory support
was for an indication of interstitial lung disease and a very small
percentage was for primary pulmonary hypertension. Do you
have any insight into the patients who had interstitial lung disease?
What was the degree of pulmonary artery hypertension, and did
that correlate with your outcomes or need for CPB versus ECMO?
Dr Biscotti. Thank you for the question. I know between the
2 groups, at the very least, there was no difference in pulmonary
arterial pressures; however, I think that this is something that could
be looked at as far as the comparison of our pulmonary artery pres-
sures in these patients versus the ones who don’t require mechan-
ical circulatory support. I think generally one of the reasons we
make the decision preoperatively that we are going to use bypass
or ECMO is because, as you know, the pulmonary arterial pres-
sures are very high, but I don’t have a subgroup analysis of just
the patients with interstitial lung disease per se.
Dr Miller. From your experience, if you have elevated pulmo-
nary arterial pressures, which would you prefer?
Dr Biscotti. It seems that ECMO does a pretty good job in our
hands.
Dr Si Mai Pham (Baltimore, Md). I have 2 questions. First, in
which patients would you recommend using ECMO versus CPB if
you need to use cardiopulmonary support during a lung transplant
operation? Second, there was a study from Germany several years
ago from Friedrich Mohr’s group in which they compared ECMO
versus CPB in lung transplant operation, and they abandoned the
use of ECMO because the ECMO group had more bleeding and
more complications. So I wonder whether you are familiar with
that work, and what are differences between your work and theirs?diovascular Surgery c Volume 148, Number 5 2415
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XDr Biscotti. Thank you for your questions. To answer your sec-
ond question first, I am not sure whether it’s the same as that 2007
study that you were talking about, but I think it could be that they
ran their anticoagulation higher; additionally some of the circuitry
is different from what we use now. Perhaps the technology wasn’t
quite there in 2007, or maybe they were using a more complex cir-
cuit than ours, which is relatively simple and less thrombogenic.
Also, they studied their lung transplant program in its infancy;
from what I understand, they had just started their program. So
it is not necessarily comparable.
And I think for your first question, why we use ECMO versus
CPB or CPB versus ECMO, I know that if we anticipate a lot of
bleeding or if will have to do some intracardiac procedure, such
as closing an atrial septal defect, then we would definitely use
CPB. But at this point in our institution, we use ECMO unless
one of those situations arises.
Dr Michael S. Mulligan (Seattle, Wash). What was your inci-
dence of limb complications in your groin access group?
Dr Biscotti. I don’t remember the exact number. I know that
there was no difference between the groups. We generally don’t
use distal perfusion cannulas if we don’t have to, only if we antic-
ipate that we will have to continue support postoperatively.
DrMulligan.What was your incidence of insufficient drainage
with groin cannulation? This is a common problem that surgeons
will talk about, and in fact it came up in the transplant symposium
yesterday that people were concerned about this. Are you seeing
this as a problem?
Dr Biscotti. I can’t answer that. I don’t know the answer to that,
but I think it is a reasonable question.
Dr Matthew Bacchetta (New York, NY). We actually have not
had to insert extra drainage cannulas. We choose cannulas
based on the expected need of the patient, which is a function of
their remaining native lung function and calculated cardiac output.
If we are doing a double-lung transplant, we approach them
sequentially and transplant the worst lung first (based on2416 The Journal of Thoracic and Cardiovascular Surventilation/perfusion scan data). This approach generally allows
us to flow at partial support levels even for patients with severe
pulmonary hypertension. We have found that 60% to 75% of
their calculated flow is more than adequate to support them
physiologically.
Regarding limb ischemia, we have not had a problem with
compromised limbs because we carefully size the femoral vessels
preoperatively with an ultrasound. If the required arterial cannula
looks close to causing limb ischemia, we cut down onto the artery
and sew a graft on it. Then, we cannulate the tunneled graft. This
approach eliminates the risk for limb ischemia.
Dr Mulligan. I may have misheard, but it sounds like you had
situations where you may have had groin venous cannulation and
central aortic cannulation, and if you are already in the chest and
you are going to centrally cannulate for a return, paint me a sce-
nario in which you wound up having sort of one purpose for
each access.
Dr Bacchetta. If the patient’s native lung function is extremely
poor and she might not tolerate partial flow with sequential trans-
plant, or if she develops severe hemodynamic instability while I
have the chest open, I can cannulate the aorta while my resident
cannulates the femoral vein. It saves a small amount of time, but
mostly it keeps the venous cannula out of the right atrium, which
can be mildly nettlesome when clamping the pulmonary veins/left
atrium.
Dr Mulligan. So this is not a planned strategy in which you
have something in the groin and something in the chest?
Dr Bacchetta. Sometimes it is part of the plan since I prefer
to keep venous cannulas out of the right atrium. I don’t like
having a dual-stage venous cannula in the atrium because, as
I mentioned earlier, it can make clamping the pulmonary
veins/left atrium more cumbersome. I usually insert the femoral
venous cannula up to the atrial-inferior vena cava junction,
which allows for good drainage while keeping it out of the right
atrium.gery c November 2014
